• LAST PRICE
    0.4000
  • TODAY'S CHANGE (%)
    Trending Down-0.0500 (-11.1111%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.4200 / 0.4500
  • Day Range
    Low 0.4000
    High 0.4200
  • 52 Week Range
    Low 0.0024
    High 1.5000
  • Volume
    24,266
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.45
TimeVolumeCLCS
01:04 ET29500.42
01:45 ET10000.42
02:03 ET25000.4
02:57 ET25000.4
02:59 ET20000.42
03:01 ET10000.42
03:03 ET10000.42
03:30 ET25000.4
03:37 ET25000.4
03:39 ET63160.4
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCLCS
Cell Source Inc
14.1M
-2.4x
---
United StatesERNA
Eterna Therapeutics Inc
14.2M
-0.5x
---
United StatesTOVX
Theriva Biologics Inc
14.3M
-0.7x
---
United StatesINDP
Indaptus Therapeutics Inc
13.8M
-1.0x
---
United StatesCEOS
CeCors Inc
13.7M
0.0x
---
United StatesGRAY
Graybug Vision Inc
14.7M
-0.4x
---
As of 2023-01-28

Company Information

Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes Chimeric Antigen Receptor (CAR) T-cell therapies, which includes VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell Kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).

Contact Information

Headquarters
57 West 57Th Street, Suite 400NEW YORK, NY, United States 10019
Phone
646-612-7554
Fax
646-612-7545

Executives

Chairman of the Board
Dennis Brown
Chief Executive Officer, Chief Financial Officer
Itamar Shimrat
Director
Darlene Soave
Director
George Verstraete

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$14.1M
Revenue (TTM)
$0.00
Shares Outstanding
35.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.17
Book Value
$-0.29
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.